Mirum Pharmaceuticals Stock Quote MIRM - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

24.07

Bid

23.27

Ask

24.86

Volume

0.00 Day's Range 0.00

23.14 52 Week Range 35.56

Market Cap

1.122B

Previous Close

24.07

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

487,282

Shares Outstanding

46,614,274

Dividend Yield

PE Ratio

-6.87

Earnings Per Share (EPS)

-3.51

Revenue

186.37M

Net Profit

-163.42M

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Dover, Delaware, USA

Founded

1970

Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MIRM. The last closing price for Mirum Pharmaceuticals was $24.07. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of $ 23.14 to $ 35.56.

Mirum Pharmaceuticals currently has 46,614,274 shares outstanding. The market capitalization of Mirum Pharmaceuticals is $1.12 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.87.

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

- Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied - Significant improvements observed across multiple parameters including pruritus, serum bile...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.08	-4.29423459245	25.15	26.27	23.99	356616	24.69575843	CS
4	0.1	0.417188151856	23.97	26.98	23.14	406117	25.03922013	CS
12	-3.65	-13.1673881674	27.72	30.23	23.14	487282	26.137381	CS
26	-8.43	-25.9384615385	32.5	35.56	23.14	579931	28.16718406	CS
52	-2.07	-7.91889824024	26.14	35.56	23.14	555734	28.21292984	CS
156	6.32	35.6056338028	17.75	35.56	12.82	364732	24.94168124	CS
260	11.07	85.1538461538	13	35.56	6.5126	280824	23.58028247	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAGRAfrican Agriculture Holdings Inc	$ 0.37 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 65.09 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.91 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.4599 (0.00%)	0
AACGATA Creativity Global	$ 0.91 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.37 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 65.09 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.91 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.4599 (0.00%)	0
AACGATA Creativity Global	$ 0.91 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.37 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 65.09 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.91 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.4599 (0.00%)	0
AACGATA Creativity Global	$ 0.91 (0.00%)	0